<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05059691</url>
  </required_header>
  <id_info>
    <org_study_id>2020-1174</org_study_id>
    <secondary_id>NCI-2021-08947</secondary_id>
    <secondary_id>2020-1174</secondary_id>
    <nct_id>NCT05059691</nct_id>
  </id_info>
  <brief_title>Three-Dimensional Fluoroscopic Guidance During Transbronchial Cryobiopsy</brief_title>
  <official_title>Three-Dimensional Fluoroscopic Guidance During Transbronchial Cryobiopsy, a Prospective Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study assesses the effectiveness of transbronchial cryobiopsy guided by 3-dimensional&#xD;
      fluoroscopy. Transbronchial cryobiopsy is a procedure to collect lung tissue. The main side&#xD;
      effect seen after a transbronchial cryobiopsy is pneumothorax (air leaking out of the lung,&#xD;
      which may cause a completely or partially collapsed lung). The standard imaging scans used&#xD;
      during this procedure are 2-dimensional (like a photo), which can make it difficult for the&#xD;
      doctor to know exactly where the biopsy tool is during the procedure. If the exact location&#xD;
      of the device is not clear, a patient can be at a higher risk of pneumothorax. Using a&#xD;
      3-dimensional imaging technique may help to decrease the risk of pneumothorax during&#xD;
      transbronchial cryobiopsy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To determine if transbronchial cryobiopsy guided by three-dimensional fluoroscopy reduces&#xD;
      the incidence of pneumothorax up to 72 hours after transbronchial cryobiopsy.&#xD;
&#xD;
      SECONDARY OBJECTIVE:&#xD;
&#xD;
      I. To describe outcomes of cryobiopsy, need for interventions related to transbronchial&#xD;
      cryobiopsy, radiation dose, and any complications or adverse events after transbronchial&#xD;
      cryobiopsy guided by three-dimensional fluoroscopy.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients undergo transbronchial cryobiopsy guided by three-dimensional fluoroscopy. Patients'&#xD;
      medical records are also reviewed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 30, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of pneumothorax</measure>
    <time_frame>Up to 72 hours after cryobiopsy</time_frame>
    <description>The proportion of patients developing pneumothorax will be compared with the proportion in the historical control (i.e., 20%) using two-sided binomial test. A p-value of less than 0.05 will indicate a statistical significance. The proportion of patients identified as developing pneumothorax and its exact 95% confidence interval will be estimated. Poisson regression model will be used to estimate the incidence of pneumothorax accounting for the number of biopsy sites.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Lung Carcinoma</condition>
  <arm_group>
    <arm_group_label>Observational (transbronchial cryobiopsy)</arm_group_label>
    <description>Patients undergo transbronchial cryobiopsy guided by three-dimensional fluoroscopy. Patients' medical records are also reviewed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Electronic Health Record Review</intervention_name>
    <description>Review of medical records</description>
    <arm_group_label>Observational (transbronchial cryobiopsy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transbronchial Cryobiopsy Guided by Three-Dimensional Fluoroscopy</intervention_name>
    <description>Undergo transbronchial cryobiopsy guided by three-dimensional fluoroscopy</description>
    <arm_group_label>Observational (transbronchial cryobiopsy)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with presence of an intraparenchymal lung lesion for which cryobiopsy is deemed&#xD;
        the most appropriate method of biopsy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Presence of an intraparenchymal lung lesion for which cryobiopsy is deemed the most&#xD;
             appropriate method of biopsy&#xD;
&#xD;
          -  Ability to provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute respiratory failure (defined as oxygen requirement &gt; 4 L/min by nasal cannula&#xD;
             above baseline, or need for any intervention to support ventilation and/or gas&#xD;
             exchange for any duration, including invasive and non-invasive positive pressure&#xD;
             ventilation, high-flow therapy, non-rebreather mask, or Venturi mask)&#xD;
&#xD;
          -  Intensive care unit (ICU) admission&#xD;
&#xD;
          -  Forced vital capacity (FVC) &lt; 50% or diffusing capacity of the lung for carbon&#xD;
             monoxide (CO) (DLCO) &lt; 35% (if pulmonary function tests are available)&#xD;
&#xD;
          -  Known or suspected pulmonary hypertension (defined as elevated right ventricular&#xD;
             systolic pressure on echocardiogram, if available)&#xD;
&#xD;
          -  Acute renal failure or chronic kidney disease&#xD;
&#xD;
          -  Platelets &lt; 100,000/uL&#xD;
&#xD;
          -  International normalized ratio (INR) &gt; 1.5&#xD;
&#xD;
          -  Use of anticoagulant therapy that cannot be held for 2 days&#xD;
&#xD;
          -  Use of antiplatelet therapy (other than baby aspirin) that cannot be held for 5 days&#xD;
&#xD;
          -  Any bleeding diathesis&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruce F Sabath</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruce F. Sabath</last_name>
      <phone>713-792-6238</phone>
      <email>bsabath@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Bruce F. Sabath</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 10, 2021</study_first_submitted>
  <study_first_submitted_qc>September 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

